Experimental lung cancer vaccine shows early promise in small trial
Disease control
Terminated
This early-phase study tested a new immunotherapy called IMU-201 in 24 adults with advanced non-small cell lung cancer. The treatment aims to help the body's immune system fight cancer by targeting a protein called PD-1. Some participants received IMU-201 alone, while others got …
Phase: PHASE1 • Sponsor: Imugene Limited • Aim: Disease control
Last updated Apr 29, 2026 02:37 UTC